Lionshead Wealth Management LLC Buys New Position in Eli Lilly and Company (NYSE:LLY)

Lionshead Wealth Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 587 shares of the company’s stock, valued at approximately $453,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Knightsbridge Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock worth $628,000 after purchasing an additional 15 shares in the last quarter. Centerpoint Advisory Group bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $514,000. Kentucky Trust Co bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $834,000. CSM Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock worth $807,000 after purchasing an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 30.2% in the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock worth $5,202,000 after purchasing an additional 1,562 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 2.0%

Shares of Eli Lilly and Company stock opened at $736.21 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $697.73 billion, a PE ratio of 62.87, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a fifty day moving average price of $810.98 and a 200-day moving average price of $810.32.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.58 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.81%. Eli Lilly and Company’s payout ratio is 48.82%.

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,002.80.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.